Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential

 
• By Alaric DeArment

The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.

Ulcerative colitis endoscopic biopsy
Roivant announced Phase IIb results for RVT-3101 in ulcerative colitis • Source: Shutterstock

More from Clinical Trials

More from R&D